Enovix Battles Credibility Gap as JPMorgan Pulls Price Target

JPMorgan downgrades Enovix to Underweight, citing scale issues and smartphone delays, despite Q4 revenue beat and new sales chief hire.

The battery developer Enovix finds itself in a precarious position: its technology is advancing, but Wall Street's patience is wearing thin. JPMorgan has delivered the most damning signal yet, downgrading the stock from "Neutral" to "Underweight" and withdrawing its $6 price target entirely. Analyst Bill Peterson's move sent shares tumbling 7% on Wednesday to around €5.50.

The downgrade cuts to the core of Enovix's investment thesis. While the company's silicon-anode battery technology promises superior energy density, competitors are closing the gap. More troubling, the markets Enovix currently serves — wearables, defense, and drones — lack the scale to drive meaningful revenue growth. The real prize remains the smartphone segment, where Enovix is still pursuing formal qualification with Chinese manufacturer Honor. Whether and when that translates into volume production remains an open question.

For fiscal 2026, JPMorgan projects a loss of $0.61 per share.

The company's fourth-quarter 2025 results offered a glimmer of hope, with revenue of $11.26 million beating the consensus estimate of roughly $10 million. Enovix also outperformed on per-share losses. But context matters. With a market capitalization near $1.46 billion and persistent losses, the company needs to crack high-volume manufacturing — something it has yet to achieve.

That helps explain why the stock has lost about 18% since the start of the year and trades more than 60% below its 52-week high.

A New Sales Chief Takes the Helm

Enovix is not standing still. The company has brought in Steve Bakos as Senior Vice President of Worldwide Sales, a newly created role. Bakos brings decades of semiconductor industry experience, including stints at Infineon where he managed key accounts like Apple. He reports directly to Chief Strategy Officer Samira Naraghi.

The hire signals that management recognizes the commercial pressure. Bakos arrives as Enovix revamps its testing protocols for smartphone batteries. The company has agreed with a major customer to replace the previous 0.7C testing standard with a more realistic evaluation framework. Current performance tests are approaching the thresholds required for broad market adoption, according to the company.

Operational attention is now fixed on ramping factories in Malaysia and South Korea.

Analyst Divide Deepens

JPMorgan's bearish stance is not universally shared. Bank of America maintains a Neutral rating, citing unresolved production questions. Oppenheimer remains more optimistic with an Outperform rating.

The stock closed recently at €5.86, having recovered from its lows but still down roughly 13% year-to-date. The next test comes in May 2026 when Enovix reports first-quarter results. Revenue in the expected range of $7 million would confirm that Asian production is on track. A miss would bring the recent low of €4.18 back into play as a technical support level.